Tilia Fiduciary Partners Inc. Sells 75 Shares of Johnson & Johnson (NYSE:JNJ)

10 Jan 2025, 23:50 by Tristan Rich · The Markets Daily

Tilia Fiduciary Partners Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 2.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,155 shares of the company’s stock after selling 75 shares during the period. Tilia Fiduciary Partners Inc.’s holdings in Johnson & Johnson were worth $456,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Sugarloaf Wealth Management LLC raised its position in shares of Johnson & Johnson by 2.0% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 6,505 shares of the company’s stock valued at $941,000 after buying an additional 127 shares in the last quarter. HBW Advisory Services LLC increased its holdings in shares of Johnson & Johnson by 2.2% in the fourth quarter. HBW Advisory Services LLC now owns 6,534 shares of the company’s stock worth $945,000 after buying an additional 141 shares during the period. Jacobs & Co. CA lifted its stake in shares of Johnson & Johnson by 0.3% in the 4th quarter. Jacobs & Co. CA now owns 56,569 shares of the company’s stock valued at $8,181,000 after acquiring an additional 179 shares during the last quarter. Sage Capital Advisors llc boosted its stake in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sage Capital Advisors llc now owns 43,731 shares of the company’s stock valued at $6,324,000 after purchasing an additional 230 shares during the period. Finally, Harbor Capital Advisors Inc. grew its holdings in Johnson & Johnson by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,879 shares of the company’s stock worth $7,214,000 after acquiring an additional 1,224 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The shares were acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Royal Bank of Canada boosted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Guggenheim increased their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Wells Fargo & Company increased their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

View Our Latest Research Report on JNJ

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ traded down $0.20 during midday trading on Friday, hitting $142.07. The company had a trading volume of 8,585,174 shares, compared to its average volume of 7,666,985. The company has a fifty day moving average of $150.03 and a two-hundred day moving average of $156.04. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The company has a market cap of $342.05 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the business earned $2.66 EPS. On average, equities research analysts expect that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.49%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.